Research and development at Ranbaxy pharmaceutical and laboratories

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited. (RLL), was established in the U.S. in 1994. RPI began marketing FDA approved generic products in the U.S. in 1998 after receiving its first FDA approval for Cefaclor, a broad spectrum anti-infective agent.


Ranbaxy Laboratories Inc. (RLI), also a wholly owned subsidiary of Ranbaxy Laboratories Limited. (RLL), is the branded prescription division in the U.S. RLI has been expanding and growing on the strength of Ranbaxy’s R&D efforts, and continuing exploration of novel drug delivery systems (NDDS), licensing activities, mergers and acquisitions. RLI is expanding the visibility and presence of the Ranbaxy name by bringing value-added brand products to the market.



Go to http://www.ranbaxyusa.com/rnd.aspx